Guntzel 1991.

Methods	4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 100‐115 mm Hg at end of 3rd and 4th week of run‐in as well as during baseline BP profile (BP measured hourly during first 10 hours and last 4 hours after last placebo capsule); 8‐week double‐blind treatment
Participants	Cilazapril 2.5 mg: n=29(17 males,12 females); mean age=56(7) years; baseline DBP=103.5 mm Hg; Cilazapril 5 mg: n=29(22 males,7 females); mean age=49(8) years; baseline DBP=103.1 mm Hg; Placebo: n=27(17 males,10 females); mean age=52(9) years; baseline DBP=104.3 mm Hg
Interventions	Cilazapril 2.5 mg once daily; Cilazapril 5 mg once daily; Placebo; taken at 10 AM
Outcomes	Trough sitting SBP/DBP using mercury sphygmomanometer; Trough HR; WDAE
Notes	Endpoint (week 8) BP change and DBP SE of change reported, endpoint BP and SD reported; BP also reported at weeks 4,6,8; calculated DBP SD of change from N and SE of change; imputed overall trial mean SBP SD of change; BP data from Figure 1, p. 10; Jadad score=3; funding source= Hoffman‐La Roche Ltd. Duplication publication = Study 2 of Kobrin 1991.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear